Mesa Laboratories INC /CO/ 8-K filings

Mesa Laboratories announced first-quarter results showing 1.0% revenue growth, a significant increase in operating income, and a reduction in its net leverage ratio.

Mesa Laboratories, Inc. has amended and restated its Code of Ethics and Business Conduct, effective immediately, to modernize policies on external communications and social media.

Mesa Laboratories, Inc. has appointed Lyndsey Crennen as its new Chief Accounting Officer, effective June 26, 2026.

Mesa Laboratories announced fourth quarter and full fiscal year 2026 results, highlighting revenue growth, increased operating income, and significant debt repayment.

Mesa Laboratories, Inc. announced CEO Gary Owens' departure, effective April 13, 2026, with a transition agreement and immediate board resignation.

Mesa Laboratories reports strong third fiscal quarter 2026 results with a 3.6% revenue increase and a significant 317% rise in net income, driven by robust BPD growth and cost realignment benefits.

Mesa Laboratories announced a 5.0% revenue increase and 34.7% operating income growth in Q2 FY26, driven by strong performance in BPD and CS, despite challenges in Clinical Genomics China.

Mesa Laboratories, Inc. announced the results of its annual shareholder meeting, confirming the election of all director nominees and the approval of all proposals, including auditor ratification and executive compensation.

Mesa Laboratories, Inc. has successfully executed its financial strategy by repaying $97.5 million in convertible senior notes using its existing credit facility, optimizing its capital structure and reducing potential shareholder dilution.

Mesa Laboratories reported a 2.4% revenue increase in Q1 FY26, but operating income declined significantly due to FX and non-cash stock-based compensation, alongside challenges in China and BPD segment delays.

Mesa Laboratories, Inc. announced a change in its independent registered public accounting firm from Moss Adams LLP to Baker Tilly US, LLP, effective June 3, 2025, following the merger of Moss Adams with Baker Tilly.

Mesa Laboratories, Inc. announced strong financial results for its fourth fiscal quarter and full fiscal year 2025, driven by double-digit revenue growth, substantial improvement in net loss, and key strategic achievements, alongside effective debt reduction.

Mesa Laboratories announces a 17.5% increase in revenue for its third fiscal quarter, driven by organic growth and the acquisition of GKE.

Mesa Laboratories announced an 8.8% increase in total revenue for the second fiscal quarter of 2025, driven by the GKE acquisition and strong biopharmaceutical demand, despite a slight organic revenue decline.

Mesa Laboratories has engaged Moss Adams as its new independent auditor, replacing RSM, effective immediately, following a request for proposal process.

Mesa Laboratories held its annual shareholder meeting on August 30, 2024, electing directors and ratifying the appointment of its independent auditor.

Mesa Laboratories announced a robust start to its fiscal year with a 14.9% revenue increase and a 47% jump in adjusted operating income excluding unusual items for the first quarter ended June 30, 2024.

Mesa Laboratories announced its fourth quarter and full fiscal year 2024 results, showing revenue growth in the quarter but a slight annual decline, alongside strategic restructuring and significant non-cash impairment charges.

Mesa Laboratories has amended its credit agreement to include a $75 million term loan and a $125 million revolving credit facility, and has repurchased $75 million of its 2025 convertible notes.

Mesa Laboratories anticipates recording approximately $271 million in non-cash impairment losses related to goodwill and intangible assets for the fiscal year ending March 31, 2024, primarily impacting its Clinical Genomics and Biopharmaceutical Development divisions.

Mesa Laboratories' third quarter results show a revenue decrease of 1.5% year-over-year, but a sequential increase of 0.6% compared to the previous quarter, with significant impacts from acquisitions and market challenges.